West Pharmaceutical Services Inc specializes in creating containment and delivery systems for injectable drugs and healthcare products. With a global presence, it offers a wide range of products including stoppers, seals, syringe components, and advanced drug delivery systems. The company focuses on enhancing the safety and quality of drug administration through innovative solutions like Crystal Zenith technology and self-injection devices. Serving the pharmaceutical, diagnostic, and medical device industries, West Pharmaceutical provides both proprietary and contract-manufactured products, backed by comprehensive support services from development to post-sales.
Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it…
West Pharmaceutical Services (NYSE: WST | WST Price Prediction) has ripped 24.2% in the past month and 8.7% in the past week, and the move has the fingerprints of a sustained re-rating.…
Trey Thoelcke West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company’s latest quarterly dividend payment. For a business that’s quietly grown its payout for over a decade,…
Joel South Dividend growth investing focuses on acquiring stocks that consistently increase their dividends, providing investors with a reliable, inflation-beating income stream and potential capital appreciation. This strategy prioritizes companies with strong fundamentals, stable…
The stock market has been on a winning streak as fears about tariffs start cooling. Earnings season has also been solid, and most tech companies have trounced estimates so far. As such,…
Tuesday's top analyst upgrades and downgrades included Activision Blizzard, Adobe, Advanced Micro Devices, Ares Capital, Intel, Lennar, Marvell Technology, NexTier Oilfield Solutions, Nike, Nvidia, SoFi Technologies, Truist Financial, Tyson Foods and ZScaler.
Wednesday's top analyst upgrades and downgrades included Antero Resources, Array Technologies, Bumble, Chewy, EQT, LendingClub, Match, MGIC Investment, Nasdaq, New York Community Bancorp, Palo Alto Networks, Radian, Range Resources, Spotify Technology and Welltower.
The big U.S. indexes traded lower in Friday's premarket, continuing the prior day's trend, and short-term bonds seem to be the place to be.
Monday's top analyst upgrades and downgrades included Altria, Amazon.com, Apple, Axalta Coating Systems, Comcast, Etsy, Intel, McDonald's and Medical Properties Trust.
The S&P 500 index is up about 2% this year, after a spring collapse and remarkable rebound. Among the companies in the index, 10 are up more than 50%.
Thursday's top analyst upgrades, downgrades and initiations included Autodesk, Bausch Health, Charles Schwab, Darden Restaurants, Garmin, GE, Home Depot, Kroger, Merit Medical and Starbucks.
Analysts at Jefferies recently reviewed several pharmaceutical services company stocks and put a Buy rating on four outstanding performers.
Lee Jackson These stocks offer investors strength in their specific industries and the ability to avoid high-flying disasters. All of them are suitable for growth accounts with some degree of risk tolerance.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
